XORTX Corp (XRTX) - Long-Term Debt to Capital Coefficient
XORTX Therapeutics Inc. (XRTX) collaborates closely with medical centers, studying kidney pathologies to develop effective therapies. The business relies on unique uric acid modulation, offering innovative treatment for polycystic kidney disease through metabolic control. The company is currently scaling programs for the use of modified oxypurinol, and the indicator stands at 0.00. The asset's price action shown below reflects the implementation of this strategic plan.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_XRTX_-_XORTX-Therapeutics-Inc._-_Long-Term-Debt-to-Capital "XRTX: XORTX Therapeutics Long-Term Debt to Capital 07/04/2022 - 11/01/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for XORTX Therapeutics Inc. (XRTX)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio XORTX Therapeutics Inc.|XRTX - Long-Term Debt to Capital|Short-Term Debt to Capital xortx.com|XRTX - Company Total Debt|Debt to Net Assets Ratio XORTX Therapeutics Inc.|XRTX - Company Long-Term Debts|Short-Term Debt Volume XORTX Therapeutics|Quick Liquidity Indicator xortx.com
- net income and valuation ratios data:
General company analysis:XORTX Therapeutics Inc - XRTX
A fundamental stress test of the position requires an analysis of the balance sheet's resilience to long-term liabilities. XORTX Therapeutics Inc. (XRTX) is developing through venture capital, focusing on clinical trials for kidney drugs. This long-term financial leverage ratio compares loans with a maturity of more than one year against net assets. An increase in this indicator signals a rising debt load relative to equity, which allows for an assessment of the business's real credit risk.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|SEPN: Long-Term Debt to Equity Ratio|PVLA (Pieris Corp) - Long-Term Debt to Capital Ratio|Savara Inc. (SVRA) - Long-Term Debt to Equity|Long-Term Liabilities to Capital rigel.com (RIGL)|Long-Term Debt to Equity AnaptysBio|ATXS: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio ENGN (enGene Bio)|Long-Term Loans to Capital Ratio RAPT|Aerovate Therapeutics - Long-Term Debt to Equity Ratio|ACRS: Long-Term Debt to Capital Ratio|KYTX: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TLSA (Tiziana Life Sciences Ltd.)|CABA (Cabaletta Bio, Inc) - Long-Term Debt to Equity Ratio|VTYX: Long-Term Loans to Capital Ratio|THTX (Theratechnologies Inc.) - Long-Term Debt to Capital|AVTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ELDN|AGEN - Long-Term Liabilities to Capital|Long-Term Debt to Equity Climb Bio, Inc. CLYM|Long-Term Debt to Capital Coefficient ZURA|aTyr Pharma, Inc. - Long-Term Debt to Capital|ADAG - Long-Term Debt to Capital|ikenaoncology.com (IMA) - Long-Term Debt to Equity|Long-Term Liabilities to Equity STTK (Shattuck Labs)|EQ (Equillium Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Connect Pharma CNTB|Long-Term Debt to Equity Ratio IMUX (Immunic, Inc.)|Long-Term Debt to Capital atarabio.com (ATRA)|InflaRx - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio XFOR (X4 Pharmaceuticals Inc.)|Adicet - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Celularity Inc. CELU|INMB: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio barinthusbio.com|Long-Term Debt to Equity Kezar Life Sciences, Inc.|SAB Biotherapeutics Inc. (SABS) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio AKTX (Akari Therapeutics plc)|ENLV (enlivex.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital QTTB (Q32 Bio)|Ratio of Long-Term Indebtedness to Capital geovax.com (GOVX)|EDSA - Long-Term Debt to Equity|IBIO (iBio Inc) - Long-Term Debt to Capital Ratio|CARM: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio XTL Bio|Long-Term Debt to Equity Ratio BOLT|HCW Biologics Inc (HCWB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio APVO (Aptevo Therapeutics)|aimimmuno.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Aditxt, Inc. ADTX|Long-Term Debt to Capital Coefficient GRI|HIND: Long-Term Debt to Equity Ratio|revbiosciences.com - Long-Term Loans to Capital Ratio|INDP (Indaptus Therapeutics, Inc.) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Ratio SCNI|Long-Term Debt to Equity CalciMedica Inc|Affimed Therapeutics - Long-Term Liabilities to Equity|Long-Term Debt to Capital ALLK|HOOK (hookipapharma.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|OCEA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|Third Harmonic Bio (THRD) - Long-Term Debt to Equity